SEC Form 4 · accession 0001562180-18-001976
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Harris
Officer — Head of Corporate Development · Director
Period of report
Apr 23, 2018
Accepted (ET)
Apr 25, 2018 · 7:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 23, 2018 | S | 525 | $20.00 | D | 571,541 | D | |
| Common Stock | Apr 24, 2018 | S | 150 | $20.00 | D | 571,391 | D | |
| Common Stock | Apr 25, 2018 | S | 300 | $20.00 | D | 571,091 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017.